MEP2508A - Tretiranje neurotskih poremećaja - Google Patents

Tretiranje neurotskih poremećaja

Info

Publication number
MEP2508A
MEP2508A MEP-25/08A MEP2508A MEP2508A ME P2508 A MEP2508 A ME P2508A ME P2508 A MEP2508 A ME P2508A ME P2508 A MEP2508 A ME P2508A
Authority
ME
Montenegro
Prior art keywords
treatment
disorder
neurotic disorders
anxiety
neurotic
Prior art date
Application number
MEP-25/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP2508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP2508A publication Critical patent/MEP2508A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-25/08A 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja MEP2508A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (1)

Publication Number Publication Date
MEP2508A true MEP2508A (xx) 2010-02-10

Family

ID=8099796

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-25/08A MEP2508A (xx) 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja
MEP-2008-25A ME00032B (me) 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-25A ME00032B (me) 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja

Country Status (38)

Country Link
US (6) US7271194B2 (de)
EP (4) EP1440691A3 (de)
JP (1) JP4773011B2 (de)
KR (1) KR100604176B1 (de)
CN (1) CN1198610C (de)
AR (1) AR021155A1 (de)
AT (1) ATE339955T1 (de)
AU (6) AU782514B2 (de)
BG (4) BG110468A (de)
BR (1) BR0011578A (de)
CA (4) CA2687392A1 (de)
CL (3) CL2008003941A1 (de)
CO (1) CO5190674A1 (de)
CY (1) CY1105806T1 (de)
CZ (1) CZ200270A3 (de)
DE (1) DE60030861T2 (de)
DK (1) DK1200081T3 (de)
EA (1) EA006555B1 (de)
ES (1) ES2272298T3 (de)
HK (1) HK1048069B (de)
HR (1) HRP20010820A2 (de)
HU (1) HUP0201791A3 (de)
IL (5) IL146131A0 (de)
IS (1) IS6137A (de)
ME (2) MEP2508A (de)
MX (1) MXPA01011626A (de)
MY (1) MY143278A (de)
NO (4) NO329021B1 (de)
PL (1) PL352030A1 (de)
PT (1) PT1200081E (de)
SI (1) SI1200081T1 (de)
SK (1) SK82002A3 (de)
TR (4) TR200402277T2 (de)
TW (1) TWI232101B (de)
UA (1) UA77645C2 (de)
WO (1) WO2001003694A1 (de)
YU (1) YU78701A (de)
ZA (1) ZA200108856B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
CA2416447A1 (en) * 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
KR20040030609A (ko) * 2001-05-01 2004-04-09 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
CA2451915C (en) 2001-07-31 2010-09-21 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
KR20050086933A (ko) * 2002-12-23 2005-08-30 하. 룬트벡 아크티에 셀스카브 브롬화수소산에스시탈로프람 및 이의 제조방법
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2007053796A2 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (de) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
EP1208838A3 (de) 1991-11-15 2003-07-09 Sepracor Inc. Reines S(+)Fluoxetin Isomer
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
DE69607904T2 (de) 1995-08-16 2000-10-05 Lilly Co Eli Potenzierung von Serotonin-Wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
CZ292911B6 (cs) * 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
WO2000000196A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
EA002977B1 (ru) * 1998-10-20 2002-12-26 Х.Лундбекк А/С Способ получения циталопрама
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
PL198024B1 (pl) * 1999-04-14 2008-05-30 Lundbeck & Co As H Sposób wytwarzania citalopramu, związki pośrednie i ich zastosowanie do wytwarzania citalopramu
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
CA2405025A1 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
KR20040030609A (ko) * 2001-05-01 2004-04-09 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도

Also Published As

Publication number Publication date
JP4773011B2 (ja) 2011-09-14
HRP20010820A2 (en) 2003-08-31
IL170192A (en) 2010-04-29
AR021155A1 (es) 2002-06-12
EP1200081B1 (de) 2006-09-20
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
US20050101665A1 (en) 2005-05-12
CA2373757C (en) 2010-01-05
EP1440689A3 (de) 2004-08-25
TR200402276T2 (tr) 2005-01-24
BG110468A (en) 2010-01-29
NO20100334L (no) 2002-01-07
IL170194A (en) 2010-05-31
NO20100335L (no) 2002-01-07
AU782514B2 (en) 2005-08-04
SK82002A3 (en) 2002-07-02
US6960613B2 (en) 2005-11-01
US7271194B2 (en) 2007-09-18
US20040029958A1 (en) 2004-02-12
AU2005202685B2 (en) 2009-01-15
CA2687392A1 (en) 2001-01-18
NO329021B1 (no) 2010-07-26
EA200200137A1 (ru) 2002-06-27
CY1105806T1 (el) 2011-02-02
US20070276035A1 (en) 2007-11-29
BG106279A (bg) 2002-08-30
ME00032B (me) 2010-02-10
NO20100333L (no) 2002-01-07
CA2687396A1 (en) 2001-01-18
DE60030861T2 (de) 2007-05-03
CL2008003939A1 (es) 2009-06-05
DK1200081T3 (da) 2006-12-27
EP1200081A1 (de) 2002-05-02
EP1440690A3 (de) 2004-08-18
AU2005202686A1 (en) 2005-07-14
ES2272298T3 (es) 2007-05-01
CN1198610C (zh) 2005-04-27
EA006555B1 (ru) 2006-02-24
AU2005202684B2 (en) 2009-01-15
KR20020015346A (ko) 2002-02-27
MY143278A (en) 2011-04-15
HUP0201791A2 (en) 2002-10-28
CL2008003938A1 (es) 2009-05-22
US20040029956A1 (en) 2004-02-12
AU2008264182A1 (en) 2009-01-29
JP2003504332A (ja) 2003-02-04
AU2005202686B2 (en) 2009-01-15
EP1440689A2 (de) 2004-07-28
EP1440690A2 (de) 2004-07-28
IL146131A0 (en) 2002-07-25
BG110466A (en) 2010-01-29
US20040029957A1 (en) 2004-02-12
AU2008264188A1 (en) 2009-05-07
WO2001003694A1 (en) 2001-01-18
PL352030A1 (en) 2003-07-28
TR200200014T2 (tr) 2002-05-21
PT1200081E (pt) 2007-01-31
NO20020062D0 (no) 2002-01-07
ATE339955T1 (de) 2006-10-15
BR0011578A (pt) 2002-03-26
CL2008003941A1 (es) 2009-05-22
BG110467A (en) 2010-01-29
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (de) 2004-07-28
YU78701A (sh) 2004-03-12
TR200402277T2 (tr) 2005-01-24
AU2005202685A1 (en) 2005-07-14
TR200402275T2 (tr) 2005-03-21
HK1048069B (zh) 2005-12-16
CZ200270A3 (cs) 2002-04-17
US7265151B2 (en) 2007-09-04
UA77645C2 (en) 2007-01-15
IS6137A (is) 2001-10-30
IL170193A (en) 2010-04-29
DE60030861D1 (de) 2006-11-02
KR100604176B1 (ko) 2006-07-25
IL146131A (en) 2007-02-11
EP1440691A3 (de) 2004-08-25
ZA200108856B (en) 2002-12-24
CO5190674A1 (es) 2002-08-29
US20020086899A1 (en) 2002-07-04
HUP0201791A3 (en) 2005-02-28
CA2687394A1 (en) 2001-01-18
HK1048069A1 (en) 2003-03-21
CA2373757A1 (en) 2001-01-18
AU5806100A (en) 2001-01-30
MXPA01011626A (es) 2002-06-04
TWI232101B (en) 2005-05-11
CN1360501A (zh) 2002-07-24

Similar Documents

Publication Publication Date Title
NO20100334L (no) Behandling av nevrotiske forstyrrelser
BR9707366A (pt) Novos aminoácidos ciclicos como agentes farmacéuticos
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
NZ515392A (en) Respiratory syncytial virus replication inhibitors
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
DK0998287T3 (da) Anvendelse af levobupivacain
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
EA200501280A1 (ru) Применение эсциталопрама для лечения приступов паники
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
EA200001162A1 (ru) Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
WO2001068067A3 (en) Use of deramciclane for the treatment of anxiety and depression
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA200501281A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
RU98114769A (ru) Способ повышения вестибулярной устойчивости человека